Virus Dataset Sample Info

> Dataset: 22195774 Search Result

Summary

Sample

ID	Sample ID	Age	Gender	Origin	Detail
1	1	42	M	Gambia	View
2	3	37	F	Gambia	View
3	5	40	M	Gambia	View
4	6	35	F	Gambia	View
5	7	28	F	Gambia	View
6	9	44	M	Gambia	View
7	10	40	M	Gambia	View
8	12	48	M	Gambia	View
9	13	36	M	Gambia	View
10	16	41	F	Gambia	View
11	17	27	M	Gambia	View
12	18	50	F	Gambia	View
13	19	24	F	Gambia	View
14	21	42	F	Gambia	View
15	22	29	F	Gambia	View
16	23	52	M	Gambia	View
17	24	29	F	Gambia	View
18	25	31	F	Gambia	View
19	26	50	M	Gambia	View
20	28	39	F	Gambia	View
21	29	30	F	Gambia	View

Literature

Item	Summary
PMID	22195774
Title	Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa.
Abstract	BACKGROUND: Lamivudine (3TC) is a potent inhibitor of both Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV) replication and is part of first-line highly active antiretroviral therapy (HAART) in the Gambia. Unfortunately, the effectiveness of 3TC against HBV is limited by the emergence of resistant strains. AIM: The aim of this retrospective study was to characterise 3TC-resistant mutations in HBV from co-infected patients receiving HAART, by generating HBV polymerase sequence data and viral loads from HBV genotype E infected patients, both at initiation and during a course of 3TC therapy. METHOD: Samples from 21 HBV chronic carriers co-infected with HIV-1 (n = 18), HIV-2 (n = 2) and HIV-dual (n = 1) receiving HAART for a period of 6-52 months were analysed for the emergence of 3TC-resistance mutations. FINDINGS: Sixteen out of 21 HBV/HIV co-infected patients responded well to HAART treatment maintaining suppression of HBV viraemia to low (